2008
DOI: 10.1590/s0004-282x2008000500012
|View full text |Cite
|
Sign up to set email alerts
|

Multiple sclerosis outcome and morbi-mortality of a Brazilian cohort patients

Abstract: -We studied the clinical and evolution characteristics of multiple sclerosis (MS) patients followed since the onset of HUCFF/UFRJ in 1978. The diagnosis of MS was based on Poser's et al. and MC Donald's et al. criteria. From 188 patients, 122 were included. Eighty-five were females. The mean age onset was 32.2 yearsold (range 6.0 to 61.0±10.3), mainly Caucasians (82/67%). The relapsing-remitting course (MSRR) was more frequent (106/86.8%). Monosymptomatic onset was significantly more frequent in Caucasians tha… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
6
0
1

Year Published

2009
2009
2023
2023

Publication Types

Select...
10

Relationship

2
8

Authors

Journals

citations
Cited by 13 publications
(7 citation statements)
references
References 26 publications
0
6
0
1
Order By: Relevance
“…After full-text review, 14 met inclusion criteria and were selected for data abstraction and analysis of incidence-prevalence (Figure 1). 1437 Information was obtained from nine countries (Figure 2). Regarding incidence, we found five studies (French West Indies, Argentina and Panama) that evaluated this issue.…”
Section: Resultsmentioning
confidence: 99%
“…After full-text review, 14 met inclusion criteria and were selected for data abstraction and analysis of incidence-prevalence (Figure 1). 1437 Information was obtained from nine countries (Figure 2). Regarding incidence, we found five studies (French West Indies, Argentina and Panama) that evaluated this issue.…”
Section: Resultsmentioning
confidence: 99%
“…Cree et al observed that 36 Africandescent compared with 616 white Caucasians with MS had a poorer response to interferon 4 . In Brazil, a third of patients with MS are African-descent 1,3 . In this context, monitoring of therapeutic responses to immunomodulators is critical for the patient, who now lives in an era of therapeutic strategies and resources that have been available for less than two decades.…”
mentioning
confidence: 99%
“…The similar clinical characteristics of ADEM and MS constitute one of the major problems among the differential diagnosis of MS and other primary inflammatory demyelinating diseases of the CNS [5][6][7]9,11,19,25,26 . ADEM has been considered a disease with favorable long term diagnosis, which is not commonly seen in patients with MS 9,11,13 .…”
Section: Discussionmentioning
confidence: 99%